CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma

Kyoungmin Lee, Kyunghye Bang, Changhoon Yoo, Inhwan Hwang, Jae Ho Jeong, Heung-Moon Chang, Dongwook Oh, Tae Jun Song, Do Hyun Park, Sang Soo Lee, Sung Koo Lee, Myung-Hwan Kim, Jin-hong Park, Kyu-pyo Kim, Baek-Yeol Ryoo

Cancer Research and Treatment. 2020;52(1):254-262. Published online 2019 July 9 DOI: https://doi.org/10.4143/crt.2019.190

Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma

J. Ha, K. Bang, C. Yoo, J. Jeong, H.-M. Chang, D. Oh, T.J. Song, D.H. Park, S.S. Lee, S.K. Lee, M.-H. Kim, J.-H. Park, K.-P. Kim, B.-Y. Ryoo

Annals of Oncology. 2019;30:ix55

Link1 Link2 Link3

Link4

Su1157 EFFICACY OF MODIFIED FOLFIRINOX AS SECOND-LINE CHEMOTHERAPY IN METASTATIC PANCREATIC ADENOCARCINOMA AFTER GEMCITABINE PLUS NAB-PACLITAXEL FAILURE

Kenji Ikezawa, Ryosuke Kiyota, Ryoji Takada, Toshihiro Imai, Abe Yutaro, Nobuyasu Fukutake, Nawa Takatoshi, Kazuhiro Katayama, Kazuyoshi Ohkawa

Gastroenterology. 2020;158(6):S-527

Link1 Link2

Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma

Cancer Research and Treatment. 2020;52(1):254-262

Link1

Link2 Link3

Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study

Yuan Zong, Jiajia Yuan, Zhi Peng, Ming Lu, Xicheng Wang, Lin Shen, Jun Zhou

Journal of Cancer Research and Clinical Oncology. 2020;147(5):1529-1536

Link1

Link2 Link3

Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer

Takafumi Mie, Takashi Sasaki, Takeshi Okamoto, Tsuyoshi Takeda, Chinatsu Mori, Takaaki Furukawa, Akiyoshi Kasuga, Masato Matsuyama, Masato Ozaka, Naoki Sasahira

Japanese Journal of Clinical Oncology. 2022;52(12):1399-1407

Link1

Link2

Incidence Of Neutropenia In Patients Receiving Either Nab-Paclitaxel Plus Gemcitabine Or Folfirinox As First-Line Treatment For Metastatic Pancreatic Adenocarcinoma

M Parisi, M Patel, K Belk, CW Craver

Value in Health. 2016;19(3):A141

Link1 Link2

<p>Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma</p>

Yuan Zong, Zhi Peng, Xicheng Wang, Ming Lu, Lin Shen, Jun Zhou

Cancer Management and Research. 2020;Volume 12:12657-12666

Link1 Link2

Modified FOLFIRINOX as a second-line treatment in pancreatic adenocarcinoma following gemcitabine plus nab-paclitaxel failure in patients with performance status two or less

A. Das, A. Dean

Annals of Oncology. 2019;30:iv83-iv84

Link1 Link2 Link3

<p>FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer</p>

Martina Catalano, Raffaele Conca, Roberto Petrioli, Monica Ramello, Giandomenico Roviello

Cancer Management and Research. 2020;Volume 12:10271-10278

Link1 Link2

Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine

Francesco Di Costanzo, Federica Di Costanzo, Lorenzo Antonuzzo, Ernesto Mazza, Elisa Giommoni

Cancers. 2023;15(2):416

Link1

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.